Aurion Biotech Completes Enrollment In Pivotal Astra Phase 3 Study, Advancing Aurn001 Toward Potential New Treatment For Corneal Edema Secondary To Corneal Endothelial Dysfunction

Aurion Biotech Inc (AURN.N)